PDE10A inhibitors also could mimic D2 antagonist effects by preferentially activating indirect pathway MSNs, offering potential therapeutic benefits for psychosis, schizophrenia, Tourette syndrome, and other movement disorders (160, 161). This evidence concerns the gene PDE10A and schizophrenia.